How effective are the ESC/EAS and 2013 ACC/AHA guidelines in treating dyslipidemia? Lessons from a lipid clinic

References

• Perk J, De Backer G, Gohlke H, et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701
   PubMed Web of Science ®Google Scholar
• Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   PubMed Web of Science ®Google Scholar
• Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40
   PubMed Web of Science ®Google Scholar
• Liberopoulos E, Vlasserou F, Mitrogianni Z, et al. Prevalence and risk distribution of residual dyslipidemia in statin-treated patients in Greece. Angiology 2012;63:184-93
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl 2):S1–S45
   PubMed Web of Science ®Google Scholar
• Barkas F, Liberopoulos EN, Kostapanos MS, et al. Lipid target achievement among patients with very high and high cardiovascular risk in a lipid clinic. Angiology 2014 May 15. pii: 0003319714535073. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Panagiotakos DB, Fitzgerald AP, Pitsavos C, et al. Statistical modelling of 10-year fatal cardiovascular disease risk in Greece: the HellenicSCORE (a calibration of the ESC SCORE project). Hellenic J Cardiol 2007;48:55-63
   PubMedGoogle Scholar
• EAS Guidelines Committee. New guidelines in USA: 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk, How do they compare with the EAS/ESC Guidelines for the management of dyslipidaemias? Available at: http://www.eas-society.org/fileArchive/2011-startpage/New%20guidelines%20in%20USA%20-%20EAS%20Comment%20-%202013-12-04.pdf [Last accessed 22 November 2013]
   Google Scholar
• Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol 2003;92:152-60
   PubMed Web of Science ®Google Scholar
• Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5
   PubMed Web of Science ®Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   Google Scholar
• Ferrieres J, Amber V, Crisan O, et al. Total lipid management and cardiovascular disease in the Dyslipidemia International Study. Cardiology 2013;125:154-63
   PubMed Web of Science ®Google Scholar
• Olsson AG, Lindahl C, Holme I, et al. LDL cholesterol goals and cardiovascular risk during statin treatment: the IDEAL study. Eur J Cardiovasc Prev Rehabil 2011;18:262-9
   PubMed Web of Science ®Google Scholar
• Santos RD, Waters DD, Tarasenko L, et al. A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: the Lipid Treatment Assessment Project 2. Atherosclerosis 2012;224:150-3
   PubMed Web of Science ®Google Scholar
• EUROASPIRE IV: adverse lifestyle trends counter improvements in CV risk factor management. Available at: http://www.escardio.org/about/press/press-releases/esc13-amsterdam/Pages/adverse-lifestyle-trends-counter-improvements-CV-risk-factor-management.aspx [Last accessed 8 December 2013]
   Google Scholar
• Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin 2011;27:1191-210
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Sibbring GC, Ballantyne CM, et al. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007;23:2009-26
   PubMed Web of Science ®Google Scholar
• Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: new statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014;11:72-4
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brandrup-Wognsen G, Palmer M, et al. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol 2010;105:69-76
   PubMed Web of Science ®Google Scholar
• Karlson BW, Palmer MK, Nicholls SJ, et al. Variability of LDL-C response with different doses of simvastatin, atorvastatin and rosuvastatin: results from VOYAGER. Abstract from 82nd EAS Congress, Madrid, Spain, 2014
   Google Scholar
• Kostapanos MS, Elisaf MS, Mikhailidis DP. Targeting cardiovascular risk: the impact of age, gender and compliance to treatment. Curr Med Res Opin 2012;28:1415-19
   PubMed Web of Science ®Google Scholar
• Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462-7
   PubMed Web of Science ®Google Scholar
• Chasman DI, Giulianini F, MacFadyen J, et al. Genetic determinants of statin-induced low-density 1420 lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet 2012;5:257-64
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. More than a billion people taking statins?: Potential implications of the new cardiovascular guidelines. JAMA 2014;311:463-4
   PubMed Web of Science ®Google Scholar
• Ray KK, Kastelein JJ, Matthijs Boekholdt S, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J 2014;35:960-8
   PubMed Web of Science ®Google Scholar
• Athyros VG, Katsiki N, Karagiannis A, et al. The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of dyslipidemia: mind the gaps! Curr Med Res Opin 2014;30(9):1-5
   PubMed Web of Science ®Google Scholar